Karpus Investment Management’s Citius Oncology CTOR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q1
Sell
-504,610
Closed -$5.52M 256
2023
Q4
$5.52M Sell
504,610
-36,000
-7% -$392K 0.17% 100
2023
Q3
$5.82M Sell
540,610
-42,665
-7% -$455K 0.2% 101
2023
Q2
$6.14M Buy
583,275
+1,050
+0.2% +$11K 0.19% 104
2023
Q1
$6.02M Buy
582,225
+318,750
+121% +$3.28M 0.19% 110
2022
Q4
$2.68M Buy
+263,475
New +$2.67M 0.09% 186

Other funds holding CTOR

Karpus Investment Management's CTOR Position: Q1 2024 in Review

Karpus Investment Management sold out of Citius Oncology (CTOR) in Q1 2024, closing a stake of 504,610 shares — an estimated $5.52M sold.

Karpus Investment Management first reported a position in CTOR in Q4 2022 and held it in 5 quarters. The position peaked at $6.14M in Q2 2023. 15 funds tracked by Wall St. Rank hold CTOR as of Q1 2024.

  • Karpus Investment Management reported no remaining Citius Oncology position as of Q1 2024 after selling out during the quarter.
  • Karpus Investment Management sold 504,610 Citius Oncology shares in Q1 2024, an estimated $5.52M.
  • Karpus Investment Management first reported a position in Citius Oncology in Q4 2022 and held it in 5 quarters.
  • Karpus Investment Management's Citius Oncology position peaked at $6.14M in Q2 2023.
  • 15 funds tracked by Wall St. Rank held Citius Oncology as of Q1 2024.

Based on Karpus Investment Management's 13F filing for Q1 2024, filed 13 May 2024.